These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28916225)

  • 1. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
    An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
    Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
    Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.
    Diao K; Bian SX; Routman DM; Yu C; Ye JC; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurooncol; 2018 Sep; 139(2):421-429. PubMed ID: 29696531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
    Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
    Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
    Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery.
    Bian SX; Routman D; Liu J; Yang D; Groshen S; Zada G; Trakul N; Wong MK; Yu C; Chang EL
    J Neurosurg; 2016 Dec; 125(Suppl 1):31-39. PubMed ID: 27903181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.
    Kiess AP; Wolchok JD; Barker CA; Postow MA; Tabar V; Huse JT; Chan TA; Yamada Y; Beal K
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):368-75. PubMed ID: 25754629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.